November/December 2013

We describe enrollment in a voluntary VBID initiative. Uptake was suboptimal, suggesting that barriers to enrollment may have significant implications for the overall effectiveness of VBID.

Among commercially insured patients treated with linezolid or vancomycin following cSSSI-related hospitalization, linezolid was associated with significantly lower rehospitalization rates and total direct medical costs.

Today's youth risk becoming the first generation not to outlive their parents. It is not too late, however, to halt and reverse this trend.

It is now time for health plans and employers to create a consumer-focused benefit.

A major opportunity to improve patient outcomes and organizational finances exists in the pharmacy service line.